PDA
The Do’s and Don’ts of Process Validation
January 12 by Helen WinsorStephen Brown, CTO of Vivalis and a Member of the Single Use Task Force, PDA, joins Helen Winsor from Pharma IQ, to discuss the application of risk management strategies when implementing single-use...
Industry To Meet As MHRA, Dutch Healthcare Inspectorate and PDA Join 30 Industry Leaders Sharing their Views on Innovation in Clinical Trial Supply Practice and Regulations
January 05 by Pharma IQ NewsIn the wake of a transformed pharmaceutical market due to mergers and acquisitions, industry leaders are to converge in Rotterdam on 27th-28th January 2011, to discuss the latest push in cost cutting...
Industry to Meet as MHRA, the Dutch Healthcare Inspectorate and the PDA Join 30 Industry Leaders Sharing their Views on Innovation in Clinical Trial Supply Practice and Regulations
November 03 by Pharma IQ NewsIn the wake of a transformed pharmaceutical market due to mergers and acquisitions, industry leaders are to converge in Rotterdam on 27th-28th January 2011, to discuss the latest push in cost cuttin...
Dr. Rafik Bishara on the New Risk Management PDA Technical Document and Risk in Today’s Biopharma Supply Chain
March 29 by Pharmaceuticals & Biotechnology EditorGeoffrey Glauser, Biomedical Advanced Research and Development Authority (BARDA), U.S. Department of Health & Human Services (HHS), interviews Dr. Rafik Bishara PhD, Technical Advisor ...
Dr. Rafik Bishara on the New Risk Management PDA Technical Document and Risk in Today’s Biopharma Supply Chain
March 29 by Pharmaceuticals & Biotechnology EditorGeoffrey Glauser, Biomedical Advanced Research and Development Authority (BARDA), U.S. Department of Health & Human Services (HHS), interviews Dr. Rafik Bishara PhD, Technical Advisor ...